WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317123
CAS#: 25451-15-4
Description: Felbamate is an anti-epileptic drug used in the treatment of epilepsy. Felbamate has been proposed to a unique dual mechanism of action as a positive modulator of GABAA receptors and as a blocker of NMDA receptors, particularly isoforms containing the NR2B subunit. Although it is clear that felbamate does cause pharmacological inhibition of NMDA receptors, the relevance of NMDA receptor blockade as a strategy for the treatment of human epilepsy has been questioned. Therefore, the importance of the effects of felbamate on NMDA receptors to its therapeutic action in epilepsy is uncertain.
MedKoo Cat#: 317123
Name: Felbamate
CAS#: 25451-15-4
Chemical Formula: C11H14N2O4
Exact Mass: 238.09536
Molecular Weight: 238.24
Elemental Analysis: C, 55.46; H, 5.92; N, 11.76; O, 26.86
Felbamate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: W-554; W 554; W554; ADD-03055; ADD03055; ADD 03055; Felbamate; brand name: Felbatol; Felbamyl; Taloxa.
IUPAC/Chemical Name: 2-phenylpropane-1,3-diyl dicarbamate
InChi Key: WKGXYQFOCVYPAC-UHFFFAOYSA-N
InChi Code: InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)
SMILES Code: NC(OCC(C1=CC=CC=C1)COC(N)=O)=O
The following data is based on the product molecular weight 238.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Shi LL, Dong J, Ni H, Geng J, Wu T. Felbamate as an add-on therapy for refractory epilepsy. Cochrane Database Syst Rev. 2014 Jul 18;7:CD008295. doi: 10.1002/14651858.CD008295.pub3. Review. PubMed PMID: 25036694.
2: Shi LL, Dong J, Ni H, Geng J, Wu T. Felbamate as an add-on therapy for refractory epilepsy. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD008295. doi: 10.1002/14651858.CD008295.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;7:CD008295. PubMed PMID: 21249704.
3: Tribut O, Bentué-Ferrer D, Verdier MC; le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique. [Therapeutic drug monitoring of felbamate]. Therapie. 2010 Jan-Feb;65(1):35-8. doi: 10.2515/therapie/2009068. Epub 2010 Mar 8. Review. French. PubMed PMID: 20205993.
4: Pellock JM, Faught E, Leppik IE, Shinnar S, Zupanc ML. Felbamate: consensus of current clinical experience. Epilepsy Res. 2006 Oct;71(2-3):89-101. Epub 2006 Aug 4. Review. PubMed PMID: 16889941.
5: Borowicz KK, Piskorska B, Kimber-Trojnar Z, Małek R, Sobieszek G, Czuczwar SJ. Is there any future for felbamate treatment? Pol J Pharmacol. 2004 May-Jun;56(3):289-94. Review. PubMed PMID: 15215558.
6: Dieckhaus CM, Thompson CD, Roller SG, Macdonald TL. Mechanisms of idiosyncratic drug reactions: the case of felbamate. Chem Biol Interact. 2002 Nov 10;142(1-2):99-117. Review. PubMed PMID: 12399158.
7: Pellock JM. Felbamate. Epilepsia. 1999;40 Suppl 5:S57-62. Review. PubMed PMID: 10530695.
8: Pellock JM. Felbamate in epilepsy therapy: evaluating the risks. Drug Saf. 1999 Sep;21(3):225-39. Review. PubMed PMID: 10487399.
9: Brown WM, Aiken SP. Felbamate: clinical and molecular aspects of a unique antiepileptic drug. Crit Rev Neurobiol. 1998;12(3):205-22. Review. PubMed PMID: 9847055.
10: Corradetti R, Pugliese AM. Electrophysiological effects of felbamate. Life Sci. 1998;63(13):1075-88. Review. PubMed PMID: 9763203.
11: Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia. 1997 Dec;38(12):1265-9. Review. PubMed PMID: 9578520.
12: Curry WJ, Kulling DL. Newer antiepileptic drugs: gabapentin, lamotrigine, felbamate, topiramate and fosphenytoin. Am Fam Physician. 1998 Feb 1;57(3):513-20. Review. PubMed PMID: 9475899.
13: Glue P, Banfield CR, Perhach JL, Mather GG, Racha JK, Levy RH. Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation. Clin Pharmacokinet. 1997 Sep;33(3):214-24. Review. PubMed PMID: 9314612.
14: Bourgeois BF. Felbamate. Semin Pediatr Neurol. 1997 Mar;4(1):3-8. Review. Erratum in: Semin Pediatr Neurol 1998 Mar;5(1):76. PubMed PMID: 9097361.
15: Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clin Pharmacokinet. 1995 Nov;29(5):341-69. Review. PubMed PMID: 8582119.
16: Pérez-Miranda J, Aguirre J, Parrilla JL, Pérez Miranda M. [Felbamate: perspectives for new antiepileptic treatment]. Rev Neurol. 1995 Nov-Dec;23(124):1220-5. Review. Spanish. PubMed PMID: 8556622.
17: Leppik IE. Felbamate. Epilepsia. 1995;36 Suppl 2:S66-72. Review. PubMed PMID: 8784215.
18: Herranz JL, Arteaga R, Armijo JA. [New antiepileptic drugs: vagabatrin, lamotrigine and felbamate]. Neurologia. 1994 Nov;9(9):410-7. Review. Spanish. PubMed PMID: 7811493.
19: Burdette DE, Sackellares JC. Felbamate pharmacology and use in epilepsy. Clin Neuropharmacol. 1994 Oct;17(5):389-402. Review. PubMed PMID: 9316688.
20: Steinhoff BJ. [The pharmacologic and clinical profile of the new anticonvulsant felbamate--an overview]. Fortschr Neurol Psychiatr. 1994 Oct;62(10):379-88. Review. German. PubMed PMID: 8001894.
